Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer
Open Access
- 18 December 2002
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Gene Therapy
- Vol. 10 (1), 57-63
- https://doi.org/10.1038/sj.cgt.7700524
Abstract
The continuous growth of tumors depends on the altered regulation of the cell cycle, which is in turn modulated by signals from growth factors and their receptors. Blockade of insulin-like growth factor (IGF)-I and IGF-IR by antisense or dominant negative plasmid transfection can suppress tumorigenicity and induce regression of established tumors. We have constructed two recombinant adenoviruses: an adenovirus expressing truncated IGF-IR (ad-IGF-IR/950) with an engineered stop codon at amino acid residue 950, and an adenovirus expressing the soluble extracellular domain of IGF-IR (ad-IGF-IR/482) with an engineered stop codon at amino acid residue 482. Ad-IGF-IR/950 produces a defective receptor with an intact α subunit and a defective β subunit lacking the tyrosine kinase domain. Dominant negative inhibition results from competition of the defective receptor with normal IGF-IR subunits, or the competition with normal IGF-IR for ligand by the soluble receptor. We were able to show here that ad-IGF-IR/950 induced the increased expression of IGF-IR on the cell surface and ad-IGF-IR/482 induced the secretion of the soluble fragment of IGF-IR. The transduction of both ad-IGF-IR/950 and ad-IGF-IR/482 could blunt the growth-stimulatory effect of IGF-I on human lung cancer cell lines. Both ad-IGF-IR/950 and ad-IGF-IR/482 effectively blocked IGF-I–induced Akt kinase activation. Intratumoral injection of ad-IGF-IR/482 virus showed significant growth suppression in established lung cancer xenografts. These findings suggest that these ad-IGF-IR/dn (950, 482) have the potential to be effective and practical cancer gene therapy strategies.Keywords
This publication has 17 references indexed in Scilit:
- The IGF-I Receptor in Cancer ResearchExperimental Cell Research, 1999
- TSH-secreting pituitary macroadenoma: Rapid tumor shrinkage and recovery from hyperthyroidism with octreotideJournal of Endocrinological Investigation, 1999
- Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death MachineryCell, 1997
- Suppression of insulin-like growth factor type I receptor by a triple-helix strategy inhibits IGF-I transcription and tumorigenic potential of rat C6 glioblastoma cellsProceedings of the National Academy of Sciences of the United States of America, 1997
- Mutant IGF-I Receptors as Dominant Negatives for Growth and TransformationBiochemical and Biophysical Research Communications, 1995
- Oncogenes and the strategy of growth factorsCell, 1994
- Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant.Proceedings of the National Academy of Sciences of the United States of America, 1994
- Chapter 8 Use of Recombinant Adenovirus for Metabolic Engineering of Mammalian CellsMethods in cell biology, 1994
- Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I.Proceedings of the National Academy of Sciences of the United States of America, 1992
- Manipulation of Adenovirus VectorsMethods in molecular biology (Clifton, N.J.), 1990